The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Specified dose on specified days
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California, United States
RECRUITINGMaximum Observed Plasma Concentration (Cmax)
Time frame: Up to Day 7
Time of Maximum Observed Plasma Concentration
Time frame: Up to Day 7
Area Under the Plasma Concentration-time Curve from Time Zero Extrapolated to Infinite Time [AUC(INF)]
Time frame: Up to Day 7
Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)]
Time frame: Up to Day 7
Apparent Terminal Phase Half-life (T-HALF)
Time frame: Up to Day 7
Apparent Total Body Clearance (CLT/F)
Time frame: Up to Day 7
Volume of Distribution of Terminal Phase (Vz/F)
Time frame: Up to Day 7
Number of Participants with Treatment Emergent Adverse Events (AEs)
Time frame: Up to Day 13
Number of Participants with Clinical Laboratory Test Abnormalities
Time frame: Up to Day 7
Number of Participants with Vital Sign Abnormalities
Time frame: Up to Day 7
Number of Participants with Physical Examination (PE) Abnormalities
Time frame: Up to Day 7
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Time frame: Up to Day 7